Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology

Gespeichert in:
Bibliographische Detailangaben
Titel: Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology
Autoren: Lamarca, Angela, Mendiola, Marta, Barriuso, Jorge
Quelle: Lamarca, A, Mendiola, M & Barriuso, J 2016, 'Hepatocellular carcinoma : Exploring the impact of ethnicity on molecular biology', Critical Reviews in Oncology/Hematology, vol. 105, pp. 65-72. https://doi.org/10.1016/j.critrevonc.2016.06.007
Verlagsinformationen: Elsevier BV, 2016.
Publikationsjahr: 2016
Schlagwörter: 0301 basic medicine, Carcinoma, Hepatocellular, Epithelial-Mesenchymal Transition, Neovascularization, Pathologic, Liver Neoplasms, Carcinoma, Hepatocellular/blood supply, Chromatin Assembly and Disassembly, Liver Neoplasms/blood supply, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Humans, Signal Transduction
Beschreibung: Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third leading cause of cancer-related death. The high rate of diagnosis in non-curable stages and the lack of novel active treatments make it necessary to review all the possible sources of misleading results in this scenario. The incidence of HCC shows clear geographical variation with higher annual incidence in Asia and Africa than in Western countries; we aimed to review the literature to find if there are different trends in the main activated molecular pathways. Hyperactivation of RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signalling and epithelial to mesenchymal transition (EMT) process are more prevalent in the Western population; however, fibroblast growth factor (FGF), transforming growth factor β (TGFβ) and Notch pathways seems to be more relevant in Asian population. Whether these variations just reflect the distinct distribution of known causes of HCC or proper ethnical differences remain to be elucidated. Nevertheless, these clearly different patterns are relevant to regional or worldwide clinical trial design. If this information is neglected by sponsors and researchers the rate of failure in HCC trials will not improve.
Publikationsart: Article
Dateibeschreibung: application/pdf
Sprache: English
ISSN: 1040-8428
DOI: 10.1016/j.critrevonc.2016.06.007
Zugangs-URL: https://www.research.manchester.ac.uk/portal/files/85440428/HCC_FINAL_accepted.pdf
https://pubmed.ncbi.nlm.nih.gov/27372199
https://www.ncbi.nlm.nih.gov/pubmed/27372199
https://www.research.manchester.ac.uk/portal/files/85440428/HCC_FINAL_accepted.pdf
https://pubmed.ncbi.nlm.nih.gov/27372199/
https://www.research.manchester.ac.uk/portal/en/publications/hepatocellular-carcinoma(cbaec746-bdb9-4c5f-bcf3-73302cddbddf).html
https://europepmc.org/abstract/MED/27372199
http://www.sciencedirect.com/science/article/pii/S1040842816301408
https://research.manchester.ac.uk/en/publications/cbaec746-bdb9-4c5f-bcf3-73302cddbddf
https://doi.org/10.1016/j.critrevonc.2016.06.007
https://pure.manchester.ac.uk/ws/files/85440428/HCC_FINAL_accepted.pdf
Rights: Elsevier TDM
Dokumentencode: edsair.doi.dedup.....0b74cc4ef322ffc1c31cc908e8bd4320
Datenbank: OpenAIRE
Beschreibung
Abstract:Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third leading cause of cancer-related death. The high rate of diagnosis in non-curable stages and the lack of novel active treatments make it necessary to review all the possible sources of misleading results in this scenario. The incidence of HCC shows clear geographical variation with higher annual incidence in Asia and Africa than in Western countries; we aimed to review the literature to find if there are different trends in the main activated molecular pathways. Hyperactivation of RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signalling and epithelial to mesenchymal transition (EMT) process are more prevalent in the Western population; however, fibroblast growth factor (FGF), transforming growth factor β (TGFβ) and Notch pathways seems to be more relevant in Asian population. Whether these variations just reflect the distinct distribution of known causes of HCC or proper ethnical differences remain to be elucidated. Nevertheless, these clearly different patterns are relevant to regional or worldwide clinical trial design. If this information is neglected by sponsors and researchers the rate of failure in HCC trials will not improve.
ISSN:10408428
DOI:10.1016/j.critrevonc.2016.06.007